Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care.

Autor: Quinn ZL; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA., Barta JA; Department of Medicine, Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University, Philadelphia, PA, USA., Johnson JM; Department of Medical Oncology, Sidney Kimmel Cancer Center, Philadelphia, PA, USA. Electronic address: Jennifer.M.Johnson@jefferson.edu.
Jazyk: angličtina
Zdroj: The American journal of the medical sciences [Am J Med Sci] 2022 Oct; Vol. 364 (4), pp. 371-378. Date of Electronic Publication: 2022 Apr 22.
DOI: 10.1016/j.amjms.2022.04.019
Abstrakt: Lung cancer remains the leading cause of cancer death in the United States and is unfortunately still frequently diagnosed in the metastatic setting, where the disease is considered incurable. Nearly 30% of these cancers may be driven by specific mutations that promote tumor growth and proliferation. These mutations are observed more frequently in young patients without significant smoking history and in certain racial and ethnic backgrounds. The past 15 years have marked a revolution for patients with molecularly driven lung cancer as novel, oral, targeted therapies have been developed that demonstrate superior activity with substantially better toxicity profiles in comparison to chemotherapy. Consideration of molecular testing for a driver mutation is imperative for all providers caring for patients with a new suspected lung cancer diagnosis, as discovery of an actionable mutation will have dramatic implications in regards to patient survival and quality of life.
Competing Interests: Declaration of Competing Interest JB reports research grants from the Genentech Health Equity Innovations Fund and the Prevent Cancer Foundation outside the submitted work.
(Copyright © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: